ClinicalTrials.Veeva

Menu

Neuro-Prävention im Rahmen Des Interventionsprojektes INVADE-2 (Follow-up Studie)

I

INVADE gGmbH

Status

Unknown

Conditions

Stroke
Dementia

Study type

Observational

Funder types

Other

Identifiers

NCT01126775
INV-1006-Gna-1000-I

Details and patient eligibility

About

"Silent" strokes are more frequent than clinical apparent strokes and can be detected noninvasively by MRI-investigations of the brain. Persons with silent strokes have a considerably increased risk for clinical apparent strokes as well as for the development of dementia. Intention of the study is the detection of silent strokes and microbleedings by standardized cranial MRI in 1000 participants (500 high-risk and 500 low-risk persons for cerebrovascular accidents) after a standardized neurological and neuropsychological examination. Results will be the base of early detection and early preventive strategies of cerebrovascular accidents in high-risk persons.

In the course of a systematic follow-up examination without MRI the same 1000 patients (500 high-risk and 500 low-risk persons for cerebrovascular accidents) will be reinvited to the sites. In addition to the standardized neurological and neuropsychological examinations a surrogate parameter of nephropathy, microalbumin, will be examined as this parameter could be helpful in forecasting cerebral microangiopathy. The clinical investigation will be expanded by several tests in order to assess symptoms of cerebral microangiopathy.

Enrollment

1,000 estimated patients

Sex

All

Ages

55+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • signed informed consent for NPV-2
  • ongoing participation in INVADE-2
  • completed participation in Neuroprävention study (NPV-1)

Exclusion criteria

  • not completed Neuroprävention study (Drop-out)
  • disagreement of notification of incidental findings
  • lack of capacity to consent of study participant
  • lack of willingness to cooperate of study participant

Trial design

1,000 participants in 2 patient groups

group non-high-risk
group high risk

Trial contacts and locations

2

Loading...

Central trial contact

Astrid Biermeier; Hans Gnahn, Dr.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems